Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The field is "still in its early stages" but may have reached an inflection point, the bank said.

Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says

An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events.

Why Novo Nordisk Stock Flopped on Friday

Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next week. It was the “stunning” numbers from the previous update of the SELECT trial in August that sent the value of the Danish pharma soaring and sparked a stampede from people to get hold of the drug.

Novo Nordisk to release clinical update on star drug Wegovy

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Danish pharma titan Novo Nordisk released its latest financial report Thursday morning. For the first nine months of 2023, the company posted double-digit percentage sales growth over the prior-year period.

Why Novo Nordisk Stock Is Surging Higher Today

The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.

Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk A/S (NVO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Daniel Bohsen - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President, Commercial Strategy and Corporate Affairs Doug Langa - Executive Vice President, North America Operations Martin Holst Lange - Executive Vice President, Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Richard Parkes - BNP Paribas Seamus Fernandez - Guggenheim Securities Peter Verdult - Citigroup Mark Purcell - Morgan Stanley Emily Field - Barclays Simon Baker - Redburn Naresh Chouhan - Intron Health Florent Cespedes - Societe Generale Richard Vosser - JPMorgan Peter Welford - Jefferies Mattias Haggblom - Handelsbanken Emmanuel Papadakis - Deutsche Bank Michael Novod - Nordea Operator Good day and thank you for standing by. Welcome to the Q3 2023 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q3 2023 Earnings Call Transcript

Eli Lilly, which makes Mounjaro, and Denmark's Novo Nordisk, which makes Ozempic and Wegovy, are struggling to meet skyrocketing demand for their medications.

Obesity Drug Demand Outstrips Supply

The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.

Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.

Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says

Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a senior executive told Reuters on Thursday.

Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic

Comcast

Li Auto Inc.

NVIDIA

Symbotic Inc

Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.

7 A-Rated Tech Stocks to Buy for November

Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from its century-long focus on insulin.

Novo Nordisk: obesity drugs priority over century-old focus on insulin

Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.

Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record Profits

Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.

Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies

Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy. Novo Nordisk (NYSE:NVO) said sales of obesity medication increased by 167% to DKr30.4 billion, while revenue from diabetes medications rose by 45%.

Novo Nordisk shares higher on bumper Wegovy boost

Novo Nordisk on Thursday reported record sales and operating profits for the third quarter but flagged continued restrictions on supplies of its hugely popular Wegovy weight-loss drug.

Novo Nordisk flags continued restrictions on Wegovy supplies

Bagsværd 2 November 2023 - Financial report for the period 1 January 2023 to 30 September 2023

Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023

The earnings report comes amid what has been a surprisingly grim two weeks for the pharmaceutical stocks.

Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drugs.

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice

FUJIFILM Holdings Corp

Novo Nordisk has hired FUJIFILM Diosynth Biotechnologies to fill Wegovy injection pens, a source familiar with the matter told Reuters, as the Danish drugmaker scrambles to boost output of its hugely popular weight-loss drug.

Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Novo Nordisk (NVO) Ahead of Earnings?

Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy.

News for Novo Nordisk Stock (NVO)